Supplemental New Drug Application submitted to FDA for Vraylar for the adjunctive treatment of major depressive disorder – AbbVie
AbbVie announced that it has submitted a supplemental New Drug Application (sNDA) for cariprazine (Vraylar) to the FDA for the adjunctive treatment of major depressive disorder (MDD) in… read more.
